The development of a factor VIII inhibitory is the most serious problem of Hemophilia A. High dose FVIII, recombinant FVIIa or FVIII inhibitor bypass activator (FEIBA) only or combined may use in the treatment of hemophilia with inhibitory. We present here 42 year-old male was admitted to our clinic with sign of shock, abdominal tenderness and image of mass. In laboratory, Hemoglobin was found 5 gr/dl, aPTT: 106 sec, FVIII: %0 and inhibitory level was found 14 BU. Abdominal computerized tomography was shown hemorrhage in abdominal cavity and in psoas muscle. In treatment; We used blood transfusion and 100 U/kgx2/d FEIBA along 4 days. General symptoms and signs was healed after 2 days and hematologic parameters turned to normal. Immune tolerans treatment program was planned for patient, later. FEIBA treatment is very useful in hemophilia patients suffered from hemorrhage and inhibitors in addition to supportive treatment
